InvestSMART

BCAL Diagnostics Limited (ASX:BDX)

ALERT: Price-sensitive ASX Announcement for BDX
Current share price for BDX : $0.079 0.006 (8.22%)+
Announcement
Release
30 Jul 2026 8:38AM
Price at Release
$0.073
Full Release
download
Summary
BCAL Diagnostics Limited, an Australian healthcare company focused on early cancer detection, provided its June 2026 quarterly report highlighting significant developments. Anne-Louise Arnett was appointed CEO, and the company advanced its BREASTEST Monitor and BREASTESTplus™ Version 2, securing a validation agreement with Sonic Healthcare USA. BCAL expanded its referral network in Australia and launched a new digital platform, EarlyDetection.com.au. Financially, BCAL secured additional funding for future activities and invested in Genetic Signatures Ltd, enhancing their strategic presence in molecular diagnostics.
Key Points
  • Anne-Louise Arnett was appointed CEO of BCAL Diagnostics Limited as of June 1, 2026.
  • Development of BREASTEST Monitor for breast cancer recurrence evaluation showed promising initial results.
  • Agreement signed with Sonic Healthcare USA for validation of BREASTESTplus™ Version 2.
  • Funding secured for FY2027 activities includes $4.9 million under a convertible note facility.
  • BCAL acquired a strategic shareholding in Genetic Signatures Ltd for $1.39 million.
  • National referral infrastructure expanded for BCAL’s early cancer detection tests.
  • BCAL launched EarlyDetection.com.au to support access to its test portfolio.
  • Cash balance at quarter end was $1.6 million, with additional funding commitments secured.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.